Move expands iPSC‑derived retinal model portfolio and strengthens position in researchAxol Bioscience has acquired the ophthalmology business of Newcells Biotech in a deal that broadens its range of induced pluripotent stem cell‑derived retinal models and reinforces its position in preclinical eye disease research.Announced in Cambridge and Newcastle on 18 February 2026, the acquisition brings Axol […]
